National Clinical Practice Guidelines

Testicular Cancer

Version 1.2004
Testicular Cancer Guidelines Expert Panel

Prof. dr. Alexandre Zlotta
Coordinator National Guidelines Testicular Cancer
Mount Sinai Hospital, Toronto (Canada)

Dr. Guy Dargent
Belgian Health Care Knowledge Centre

Prof. dr. Jacques De Grève
Chairman Working Party Manuals
College of Oncology
Universitair Ziekenhuis Brussel

Dr. Margareta Haelterman
Federal Public Service Health, Food
Chain Safety and Environment

Prof. dr. Dirk Ramaekers
Belgian Health Care Knowledge Centre

Prof. dr. Simon Van Belle
Chairman College of Oncology
University Hospital Ghent

External reviewers

The following institutions have participated in the elaboration or reviewing process of the guidelines:

➢ Belgian Society of Medical Oncology
➢ Belgian Association of Urology (BAU): Working Group Oncology
➢ Association Belge de Radiothérapie-Oncologie / Belgische Vereniging voor Radiotherapie–Oncologie
➢ College of Medical Imaging and Nuclear Medicine

This report was supported by the Belgian Healthcare Knowledge Centre. The full scientific report can be consulted at the KCE website (www.kce.fgov.be).

TESTICULAR CANCER

Expert panel and external reviewers

Treatment algorithms
- General algorithm
- Treatment in seminoma CS I after orchidectomy
- Treatment in seminoma CS IIA & B
- Treatment in non seminoma CS I after orchidectomy
- Treatment in non seminoma CS IIA & B
- Treatment in advanced disease

National guidelines testicular cancer (Full text)
- Introduction
- Clinical questions
- Search for evidence
- Diagnosis
- Clinical staging
- First multidisciplinary team meeting (MOC)
- Surgical procedure
- Histological procedure
- Final staging
- Treatment
  - Seminoma CS I
  - Seminoma CS II A and B
  - Non seminoma CS I
  - Non seminoma CS II A & B
  - Advanced disease
  - Management of unresectable metastases
- Follow-up
- References
- Table1: pTNM staging
- Table 2: TNM stage grouping
- Table 3: Prognosis table
- Table 4: Chemotherapy protocol for advanced disease
- Appendix 1: Evidence table and agree scores
- Appendix 2: Key to evidence statements and grades of recommendations
TESTICULAR CANCER

Clinical presentation
GP or specialist

Diagnostic procedure

Family assessment

Psychosocial help?

Patient consultation

Preoperative procedure

Orchidectomy

Histology

Staging

MOC: final staging

Psychosocial help?

Patient consultation

Seminoma
Stage I

Seminoma
Stage II

Non seminoma
Stage I

Non seminoma
Stage II

Stage IIA & markers
+or
Stage IIB & markers +/-

Markers -

Metastatic germ cell tumour

Adjuvant chemotherapy or Radiotherapy
(See algorithm)

Adjuvant radiotherapy
(See algorithm)

Chemotherapy or Surveillance or RPLND
(See algorithm)

Adjuvant radiotherapy
(See algorithm)

Surveillance or RPLND
(See algorithm)

Surveillance or RPLND
(See algorithm)
Seminoma CS I
(Full text)

Adjuvant irradiation of retroperitoneal paraaortic lymphatics with 20 Gy
Relapse rate 3-4%

Adjuvant carboplatin (1 cycle AUC7)
Relapse rate 3-4%

Surveillance
Relapse rate 15-20%

Relapse

Systematic relapse: Chemotherapy (BEP)
Locoregional relapse: Radiotherapy or chemotherapy

Cure rate ≥ 99%

Taken from EGCCCG guidelines
Seminoma CS IIA
(lymph nodes ≤ 2 cm)
(Full text)

- Irradiation
  - paraaortic and ipsilateral iliac nodes
  - 30 Gy (2 Gy, 5x/week)

Seminoma CS IIB
(lymph nodes 2-5 cm)
(Full text)

- Irradiation
  - paraaortic and ipsilateral iliac nodes
  - 36 Gy (2 Gy, 5x/week)

- If not willing to undergo irradiation
  - Chemotherapy
    - PEB x 3 or
    - PE x 4
Non-Seminoma CS I

Low risk
no vascular invasion present

- Standard option
  - Surveillance

- Options if conditions against surveillance
  - Adjuvant chemotherapy 2 cycles BEP

- Options if conditions against surveillance or chemotherapy
  - Nerve sparing RPLND

High risk
vascular invasion present

- Standard option
  - Surveillance

- Options if conditions against surveillance
  - Adjuvant chemotherapy 2 cycles BEP

- Options if conditions against surveillance or chemotherapy
  - Nerve sparing RPLND

Relapse

Treatment according to the IGCCG classification
(3-4 cycles BEP (or VIP) followed by resection in case of residual tumour)
TESTICULAR CANCER

Table of contents

- CS IIA, marker +
  - CS IIB, markers +/-
    - Chemotherapy
      - BEP x 3
  - Nerve sparing (NS)
  - RPLND
  - PS I
  - Follow up independent of vascular invasion
  - Resection
  - PS IIA/B
  - Follow up
  - 2 cycles BEP

- CS IIA, marker –
  - Follow-up
    - Every 6 weeks
  - Nerve sparing (NS)
  - Follow-up
    - 2 cycles BEP
  - PD
  - NC
  - Regression

*Follow-up*

Taken from EGCCCG guidelines
Testicular Cancer

Advanced Disease

### Seminoma / non-seminoma, advanced disease

**Prognostic group (GCCCG-classification)**

- **Good**
  - PEB x 3
  - If conditions against Bleomycin: PE x 4
  - Schedule: Platinum day 1,2 or 1-5
  - Etoposide day 1-3 or 1-5

- **Intermediate / poor**
  - PEB x 4
  - 5-day schedule only
  - If conditions against Bleomycin: PEI (VIP)

**Residual Tumour**

- **Marker normalized**
  - Resectable disease
    - Resection
      - Necrosis or diff. teratoma
      - Complete resection < 10% viable tumor cells
      - Follow-up
    - Consolidation chemotherapy (e.g. VIP x 2)

- **Marker elevated but plateau**
  - Follow-up 4-2 weeks
  - No increase of markers
  - Incomplete resection of viable tumour

- **Marker increase after short**
  - Interval (or while cTx)
    - Increase of markers
    - Salvage chemotherapy: PEI/VIP; VeIP; TIP
      - If platinum not possible/not active: Paclitaxel/Gemcitabine

Taken from EGCCCG guidelines

V1.2004 © 2007 College of Oncology
INTRODUCTION

The guidelines presented covers diagnosis, treatment and follow up of testicular cancer. It is based on the existing international guidelines which have been critically appraised (appendix 1) and on the consensus of national societies.

We will go through the following topics:
- diagnosis
- clinical staging
- first multidisciplinary team meeting
- surgical procedure
- histological procedure
- final staging (2d MDT meeting)
- treatment
- follow up

The grade of recommendation is stated in the text as follow:
- GR A = Evidence derived from RCT or meta-analysis or systematic review of RCT
- GR B = Evidence from non-randomised controlled trials or observational studies
- GR C = Professional consensus, or case reports or case series

The key to evidence statements and grade of recommendations are presented in appendix 2.

CLINICAL QUESTIONS

The clinical questions of this guideline are the following:
- What is the evidence for testicular cancer diagnosis management? Are there various options and if so, what is the link between an option and a specific patient subgroup?
- What is the evidence for testicular cancer therapy management? Are there various options and if so, what is the link between an option and a specific patient subgroup?
- What is the evidence for testicular cancer follow up management?

SEARCH FOR EVIDENCE

The keywords used for testicular cancer were “testicular with cancer and neoplasm”. The National guideline Clearinghouse (1 reference) and Pubmed (11 references, limit: practice guidelines) were searched in December 2004 without date limit or language restriction. The websites of known agencies were systematically searched (Europe: ESMO, European Association of Urology, The Netherlands: Oncoline, UK: NICE, Scotland: SIGN, CANADA: Ontario Cancer care, USA: NCCN, NIC, ASCO, France: ANAES, FNCLCC. Two search engines were also searched (Google and Journalservice for medics) with the same keywords than mentioned earlier.
Finally a search for systematic reviews in the Cochrane database and in DARE (4 references) was performed.

**DIAGNOSIS**

**Patient's history**

A *personal history* has to be taken. The diagnostic procedure is generally indicated for patients with the following symptoms: swelling, pain, sensation of scrotal heaviness [1] (GR B). The clinical presentation is typically a young man with testicular mass and/or pain in the back [2] (GR C). In a minority of patients, the clinical presentation is extra gonadal (retroperitoneal or mediastinal) [1-5] (GR C).

The following elements have to be detected: undescended testis, early age of puberty and sedentary life style 4, and contralateral testis tumour [1-5] (GR B).

A *family history* has to be taken: testicular tumour in any first grade relative? [2,4,5] (GR B).


*Markers*: α Feto-Protein and HCG for distinction between seminoma and non seminoma [1,2,4,5] (GR B) and for the follow up of patients with teratoma [1] (GR B). In case of advanced disease: LDH in addition, as prognostic factor [1,5] (GR B).

*Imaging*: Testicular sonography (7.5 MHz transducer) [1,2,5] (GR B) except if clinically evident [1] (GR B).

*Biopsy*: in case of symptoms with no elevation of markers [1,5] and for contralateral testis (open or needle biopsy) [1,2] (GR B).

The biopsy must give answers to the following questions:

- Presence or absence of Carcinoma in situ (GR C)
- Degree of spermatogenesis (GR C)
- Evidence of atrophy of seminiferous tubules [1] (GR B).

**CLINICAL STAGING**

To detect metastases, the following examinations are recommended:

*Imaging*

- CT scan of abdomen and pelvis [1,4] (GR B)
- Chest CT scan except for seminoma stage I [1,4,5] (GR B)
- MRI of chest and abdomen if CT contraindicated, (GR C)
- CT scan or preferably MRI of CNS: only in advanced disease with intermediate or poor prognosis, or if symptoms (GR C)
- PET scan: cfr HTA report of KCE (http://www.kenniscentrum.fgov.be/documents/D20051027330.pdf): Staging: Due to the difficulties for classical imaging techniques to evaluate small volume metastasis, every patient receives chemotherapy or radiotherapy (or retroperitoneal lymph nodes resection) but this is not needed in 70% of patients with non germ cell tumour and in 80% of patients with germ cell tumour. Nevertheless, the sensitivity of PET between 70% and 90% with specificity between 94% and 100% is not high enough to diminish the value of adjuvant therapies in case of negative results. Indeed the risk of a false negative result for nodes smaller than 1 cm is too high.
cTNM
Pre-treatment clinical classification, based on clinical examination, imaging, biopsy, (TNM classification for testicular cancer UICC, 2002 Sixth Edition) [5].

<table>
<thead>
<tr>
<th>N Regional Lymph Nodes clinical</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>NX</td>
<td>Regional lymph nodes cannot be assessed</td>
</tr>
<tr>
<td>N0</td>
<td>No regional lymph node metastasis</td>
</tr>
<tr>
<td>N1</td>
<td>Metastasis with a lymph node mass 2 cm or less in greatest dimension or multiple lymph nodes, none more than 2 cm in greatest dimension</td>
</tr>
<tr>
<td>N2</td>
<td>Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension, or multiple lymph nodes, any one mass more than 2 cm but not more than 5 cm in greatest dimension</td>
</tr>
<tr>
<td>N3</td>
<td>Metastasis with a lymph node mass more than 5 cm in greatest dimension</td>
</tr>
</tbody>
</table>

The fertility issues must be discussed with the patient: sperm banking, testosterone replacement and contraception [1] (GR B).

Information about local support services should be made available to both the patient and their relatives. Healthcare professionals should respect patients' wishes to be involved when making plans about their own management (GR C).

The need for a psychosocial help must be evaluated and, if required, the help has to be started [1] (GR C).

SURGICAL PROCEDURE

The patient is always oriented to surgery (inguinal orchidectomy) which remains the only curative option [1,2,4,5] (GR C). There is no need for emergency surgery [2] (GR C).

A preoperative risk assessment should be performed according to the appropriate guidelines (www.kenniscentrum.fgov.be/fr/Publications.html).

Every patient with a suspected testicular mass must undergo inguinal exploration with exteriorization of the testis within its tunics, and immediate orchidectomy with division of the spermatic cord at the internal inguinal ring has to be performed if a tumour is found [1,2,4,5] (GR B).

If the diagnosis is not clear, a testicular biopsy is taken for frozen section histological examination. Once the diagnosis of testicular tumour has been established, the testis is enveloped into the sponges which protected the surgical field, gloves are changed, the inguinal channel is opened and the spermatic cord is divided at the level of the internal ring. The specimen is sent for definitive histology [1,2,4,5] (GR B).

It must be explained to patients preoperatively that this procedure is being done to exclude any cancer in a situation where there is high index of...
suspicion and that following such a bivalving procedure in those situations where malignancy is not confirmed and where the testis is replaced there may be moderate to severe testicular damage [1] (GR C).

It is said that in case of disseminated disease and life-threatening metastases, up-front chemotherapy can be started and orchidectomy delayed until clinical stabilisation [5] (GR C).

From time to time a total exploration is performed for what is thought to be an inflammatory non malignant condition but tumour is found and it is necessary to proceed to orchidectomy. In this situation there is no need to perform secondary wound excision and the postoperative management should continue in exactly the same way as if the operation had been performed through the conventional inguinal approach [1] (GR B).

A testicular prosthesis should be offered to all patients [1] (GR B).

**HISTOLOGICAL PROCEDURE**

After surgical ablation of the testis, pathological assessment is mandatory and determination of serum tumour markers is advisable [5] (GR B).

Mandatory pathological requirements 2 (GR C):

- **Macroscopic features:** side, testis size, tumoural maximum size and macroscopic features of epididymis, spermatic cord and tunica vaginalis 1 (GR C).
- **Sampling:** 1 cm$^2$ section for every cm of maximal tumoural diameter, including normal macroscopic parenchyma (if present), albuginea and epididymis selection of suspected areas. At least one proximal and one distal section of spermatic cord plus any suspected area (GR C).
- **Microscopic features and diagnosis 1:** histological type (specify individual components and estimate amount as percentage) (GR C).
- **Presence or absence of peri-tumoral venous and/or lymphatic invasion 3 (GR B).**
- **Presence or absence of albuginea, tunica vaginalis, epididymis or spermatic cord invasion (GR C).**
- **Presence or absence of intratubular germinal neoplasia (Tin) in non-tumoral parenchyma (GR C).**
- **Category pT category according to TNM 2002.**
- **Immunohistochemical studies:** in seminoma and mixed germ cell tumour, AFP and beta-hCG 3 (GR B).
- **Advisable immunohistochemical markers**
  - In seminoma: cytokeratins (CAM 5.2), PLAP
  - In intratubular germ cell neoplasia: PLAP
  - Other advisable markers: Chromogranine A (Cg A), Ki 1, and NSE 5 (GR C).

The histological report must contain the following items:

- Localisation
- Multiplicity
- Gross Description: Size of Testis, Size of Tumour,
- Features: Haemorrhage, Necrosis, Cysts
- Number of blocks of tumour taken
- Germ Cell Tumour Components (WHO descriptive terms)
  - Seminoma (presence of syncitiotrophoblasts), NSGCT (Differentiated somatic elements, Embryonal Carcinoma, Syncytiotrophoblast, Yolk Sac Tumour, Choriocarcinoma, Other)
- Other tumour type
- Invasion: Vascular space invasion, cut end of cord, confined to testis, invades rete, invades tunica albuginea, invades epididymis, present in cord, invades scrotum
Other features: areas of scarring only, biopsy of contralateral testis? Intra Tubular Germ Cell Neoplasia present?

The tumour must be classified according to the WHO 2 (GR C).

**WHO classification of germ cell tumours of the testis:**

Tumours of one histological type
- Seminoma
- Spermatocytic seminoma
- Embryonal carcinoma
- Polyembryoma
- Teratoma: Mature, immature, with malignant transformation
- Yolk sac tumour (endodemal sinus tumour)
- Choriocarcinoma

Tumours of more than one histological type
- Embryonal carcinoma with teratoma (teratocarcinoma)
- Choriocarcinoma and any other types (specify)
- Other combinations (specify)

If possible, the general practitioner of the patient should attend this meeting. If not, the staging has to be fully and clearly communicated to the GP and/or specialist of the patient (GR C).

Depending on tumour stage, the further treatment options are decided. The adjuvant chemotherapy regimen is decided during the multidisciplinary team meeting. A written report with staging and treatment options is mandatory for each patient (GR C).

**TREATMENT**

A decision tree of the treatment in general is presented here.

**Seminoma CS I**

A decision tree is presented here.

There are three main options to treat a Seminoma stage I. The decision must be based on a discussion with the patient, taking into account the benefits and disadvantages of each strategy as well as the individual situation (GR C).

Adjuvant radiotherapy of retroperitoneal para-aortic lymphatic field with a total target volume of 20 Gy with modern radiotherapy (linear accelerator) [1,2,5] (GR B). This is the standard treatment for Stage I T1 to T3 patients with undisturbed lymphatic drainage [5] (GR C). The dose is applied in single doses of 2 Gy, five fractions per week [1,2] (GR B). The upper field margin is defined by D11 and the lower field margin by L5. The lateral field should include the ipsilateral renal hilum and the contralateral processus transversus of the lumbar vertebrae [1,2] (GR A).

**FINAL STAGING**

Testicular cancers should be staged using the TNM staging system: pTNM: post-surgical histopathological classification (Table 1 and table 2). The staging is done during the second multidisciplinary meeting (MOC) on the basis of all results and reports (GR C).
Surveillance is also an option due to the fact that 20% of patients only relapse after orchidectomy, and due to the potential risk of subsequent cancer following radiotherapy [2,5](GR C). This strategy is not valid in case of doubt about patient's compliance [1](GR B) and must take into account the greater psychological stress due to higher risk of relapse [2](GR C). On the contrary this strategy may be recommended for patients with horseshoe or pelvic kidney, inflammatory bowel disease or prior radiotherapy [6](GR C).

The risk factors for relapse are a tumour size > 4 cms and invasion of rete testis. Surveillance requires a prolonged and more intensive follow-up (repeated imaging examination of the retroperitoneal nodes for at least 5 years after orchidectomy) [2,5](GR B). In case of relapse, a more intensive treatment is needed but with equivalent results to the adjuvant radiotherapy [2,5](GR C).

Adjuvant carboplatin chemotherapy with one cycle of carboplatin AUC7 (7X [glomerular filtration rate + 25] mg). This strategy may reduce the occurrence of second primary testicular germ-cell tumours following radiotherapy. However, the findings need to be confirmed [7](GR C).

The relapse rate is the same for chemotherapy and for radiation therapy but with other localisation (more retroperitoneal lymph node relapse with chemotherapy >< more pelvic lymph node relapse with irradiation) [2,5](GR A).

### Seminoma CS II A and B

A decision tree is presented here.

The standard treatment is radiotherapy [1](GR B). Target volume includes the paraaortal and ipsilateral iliac lymphatics [1,2](GR B).

- Upper field margin: upper border of D11 [1,2](GR B)
- Lower field margin: upper border of the acetabulum [1](GR B)
- Lateral field:
  - for CS IIA: the same as for CSI [1](GR B);
  - for CS IIB: lateral field margins are individually modified according to the extension of the lymph nodes with a safety margin of 1 – 1.5 cm [2](GR B)
- Radiation doses: 30 Gy for CSIIA and 36 Gy for CSIIIB, homogeneously with single dose of 2 Gy at five fractions per week [2](GR C).
- Shielding of the remaining testicle is mandatory 2(GR C).

Three months after radiation therapy, abdominal and pelvic CT should be performed (basis for follow up) [2](GR B).

An alternative strategy for patients not willing radiotherapy is 3 cycles BEP or 4 cycles PE [2,5](GR B).

BEP and PE regimens (every 3(4) weeks)
- **BEP:** Cisplatin 20mg/m2, days 1-5 and hydration
- **Etoposide:** 120mg/m2, days 1,3,5
- **Bleomycin:** 30mg, days 2,9,16
- **PE:** etoposide 100mg/m2, days 1-5

Availability and reimbursement policy of the chemotherapy regimens in Belgium may be checked at:


### Non Seminoma CS I

A decision tree is presented here.

The most important prognosis factor for relapse is vascular invasion.
In case of low risk (no vascular invasion), the standard treatment is follow up 1 2 (GR B). In case of relapse, a chemotherapy treatment will result in a cure rate close to 100% [1,2] (GR B).

In case of high risk (vascular invasion), the standard treatment is 2 cycles of BEP. For several reasons like patient choice, surveillance only may be an option, with a cure rate > 98% in case of relapse cured by chemotherapy [1,2] (GR B).

In both cases, a third option is possible: nerve sparing lymphadenectomy, with a risk of recurrence or relapse of +/- 10% [2] (GR C).

Non Seminoma CS II A & B

A decision tree is presented here.

Patients with abnormal serum tumour markers AFP/HCG and/or LDH are treated depending of the prognosis (Table 3).

In case of good prognosis, 3 cycles of BEP and if Bleomycin is contraindicated, 4 cycles of Carboplatin and Etoposide (PE) can be given [2] (GR A).

Patients with retro-peritoneal lymph nodes (1-2 cms) suspected to be CS II A without tumour markers: either:

- Staging and nerve sparing Retro Peritoneal Lymph Nodes Dissection 2 (GR C). If pathology stage is I, surveillance is recommended 2 (GR B). If pathology stage is II A or B, surveillance or 2 cycles BEP [2] (GR A) or
- Surveillance with a follow up at short intervals (6 weeks) 2 (GR C): if regression of the tumour, surveillance 2 (GR C); if no change or progression of the disease with negative markers RPLND or surveillance 2 (GR C); if progression of the disease with positive markers, 3 cycles BEP and resection of the residual tumour [1,2] (GR B).

Advanced disease

A decision tree is presented here.

For patients with advanced disease, treatment is based on the prognosis evaluation, according to IGCCCG criteria (Table 3).

For patients with good prognosis disease, standard treatment is 3 cycles of BEP. In case of contraindication of bleomycin, 4 cycles of cisplatin and etoposide(PE) [2] (GR A).

For intermediate and poor prognosis patients, the 5 day BEP regimen for four cycles is the standard treatment [2] (GR A).

For intermediate prognosis patients, the treatment is given in prospective trials to design more effective treatments [2] (GR C).

For brain metastases, resection if the metastases are accessible, followed by curative or palliative radiotherapy [1] (GR C) in addition to systemic chemotherapy [2] (GR C).

Patients with seminoma who have residual masses following chemotherapy can generally be managed by surveillance. Surgery is not routinely indicated [1,2] (GR B).

Cisplatin based salvage chemotherapy is indicated after first line therapy with BEP: 4 cycles of Cisplatin, etoposide and ifosfamide (PEI), etoposide, ifosfamide and cisplatin (VIP) or vinblastine, ifosfamide and cisplatin (VEIP) or paclitaxel, ifosfamide and cisplatin (TIP) [2] (GR B).

For the treatment of late relapse, surgery should be considered [1] (GR B).

The chemotherapy regimens are presented in Table 4.
Management of unresectable metastases

Each patient should receive an evaluation for first and second line chemotherapy. The most important parameter therefore is the health performance status (GR C). The patient assessment and decision about treatment options should be done during the multidisciplinary team meeting, in presence of the patient’s general practitioner. The role of the pain clinic in pain management has to be discussed (GR C).

The need for a psychosocial help must be evaluated and, if required, the help has to be started (GR C).

Patients with advanced cancer may benefit both from treatment of the cancer and from palliative care. These are concomitant approaches to management (GR C). Palliative care specialists should be members of, and integrated with, cancer multi-disciplinary teams; their role includes the provision of education and advice for other health professionals and direct patient management (GR C).

A patient in good health status and progressing despite standard therapy should be proposed a clinical trial protocol (GR C).

FOLLOW UP

Large differences exist in the risk of recurrence or progression for patients with germ cell cancer due to differences in stage at initial presentation and individual management decisions. The intensity of the follow up depends on these factors. There is limited information about the optimal follow up procedure [2] (GR C).

Early identification of therapeutic failure in Non seminomatous Germ cell tumours by assessing serum tumour markers decline during chemotherapy is still not ready for routine clinical use [8].

For residual mass evaluation, there is evidence of diagnosis accuracy, but no evidence that PET scan results change the patient management. For therapeutic response and detection of occult recurrence, there is a lack of evidence for the use of PET (cfr HTA report of KCE (http://www.kenniscentrum.fgov.be/documents/D20051027330.pdf)
References

1 SIGN, management of Adult Testicular germ cell Tumours, SIGN, Editor. 1998.
3 NICE, Guidance on Cancer Services Improving Outcomes in Urological Cancers, NICE, Editor. 2002.
5 NCCN, testicular Cancer, NCCN, Editor. 2005.
8 Oncoline, Coloncarcinoom, O.v.v.l. kankercentra), Editor. 2000.
9 NCI, Testicular cancer treatment, NCI, Editor. 2003.
# TNM classification for testicular cancer (UICC, 2002 Sixth Edition) [1,5]

<table>
<thead>
<tr>
<th>pT</th>
<th>Primary Tumour</th>
</tr>
</thead>
<tbody>
<tr>
<td>pTX</td>
<td>Primary tumour cannot be assessed</td>
</tr>
<tr>
<td>pT0</td>
<td>No evidence of primary tumour (e.g., histologic scar in testis)</td>
</tr>
<tr>
<td>pTis</td>
<td>Intratubular germ cell neoplasia (carcinoma in situ)</td>
</tr>
<tr>
<td>pT1</td>
<td>Tumour limited to testis and epididymis without vascular/lymphatic invasion: tumour may invade tunica albuginea but not tunica vaginalis</td>
</tr>
<tr>
<td>pT2</td>
<td>Tumour limited to testis and epididymis with vascular/lymphatic invasion, or tumour extending through tunica albuginea with involvement of tunica vaginalis</td>
</tr>
<tr>
<td>pT3</td>
<td>Tumour invades spermatic cord with or without vascular/lymphatic invasion</td>
</tr>
<tr>
<td>pT4</td>
<td>Tumour invades scrotum with or without vascular/lymphatic invasion</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>pN</th>
<th>Regional Lymph Nodes</th>
</tr>
</thead>
<tbody>
<tr>
<td>pNX</td>
<td>Regional lymph nodes cannot be assessed</td>
</tr>
<tr>
<td>pN0</td>
<td>No regional lymph node metastasis</td>
</tr>
<tr>
<td>pN1</td>
<td>Metastasis with a lymph node mass 2 cm or less in greatest dimension and 5 or fewer positive nodes, none more than 2 cm in greatest dimension</td>
</tr>
<tr>
<td>pN2</td>
<td>Metastasis with a lymph node mass &gt;2cm but &lt;5cm in greatest dimension; or &gt;5 nodes positive, none &gt;5cm; or evidence or extranodal extension of tumour</td>
</tr>
<tr>
<td>pN3</td>
<td>Metastasis with a lymph node mass more than 5 cm in greatest dimension</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>M</th>
<th>Distant Metastasis</th>
</tr>
</thead>
<tbody>
<tr>
<td>MX</td>
<td>Distant metastasis cannot be assessed</td>
</tr>
<tr>
<td>M0</td>
<td>No distant metastasis</td>
</tr>
<tr>
<td>M1a</td>
<td>Non-regional lymph node(s) or lung</td>
</tr>
<tr>
<td>M1b</td>
<td>Other sites</td>
</tr>
</tbody>
</table>
## TNM Stage grouping

<table>
<thead>
<tr>
<th>Stage</th>
<th>pT</th>
<th>Tis</th>
<th>N</th>
<th>M</th>
<th>S</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 0</td>
<td></td>
<td>pTis</td>
<td>N0</td>
<td>M0</td>
<td>S0</td>
</tr>
<tr>
<td>Stage I</td>
<td>pT1-4</td>
<td>N0</td>
<td>M0</td>
<td>SX</td>
<td></td>
</tr>
<tr>
<td>Stage IA</td>
<td>pT1</td>
<td>N0</td>
<td>M0</td>
<td>S0</td>
<td></td>
</tr>
<tr>
<td>Stage IB</td>
<td>pT2</td>
<td>N0</td>
<td>M0</td>
<td>S0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>pT3</td>
<td>N0</td>
<td>M0</td>
<td>S0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>pT4</td>
<td>N0</td>
<td>M0</td>
<td>S0</td>
<td></td>
</tr>
<tr>
<td>Stage IS</td>
<td>Any pT/TX</td>
<td>N0</td>
<td>M0</td>
<td>S1-3</td>
<td></td>
</tr>
<tr>
<td>Stage II</td>
<td>Any pT/TX</td>
<td>N1-3</td>
<td>M0</td>
<td>SX</td>
<td></td>
</tr>
<tr>
<td>Stage IIA</td>
<td>Any pT/TX</td>
<td>N1</td>
<td>M0</td>
<td>S0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Any pT/TX</td>
<td>N1</td>
<td>M0</td>
<td>S1</td>
<td></td>
</tr>
<tr>
<td>Stage IIB</td>
<td>Any pT/TX</td>
<td>N2</td>
<td>M0</td>
<td>S0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Any pT/TX</td>
<td>N2</td>
<td>M0</td>
<td>S1</td>
<td></td>
</tr>
<tr>
<td>Stage IIC</td>
<td>Any pT/TX</td>
<td>N3</td>
<td>M0</td>
<td>S0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Any pT/TX</td>
<td>N3</td>
<td>M0</td>
<td>S1</td>
<td></td>
</tr>
<tr>
<td>Stage III</td>
<td>Any pT/TX</td>
<td>Any N</td>
<td>M1</td>
<td>SX</td>
<td></td>
</tr>
<tr>
<td>Stage IIIA</td>
<td>Any pT/TX</td>
<td>Any N</td>
<td>M1a</td>
<td>S0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Any pT/TX</td>
<td>Any N</td>
<td>M1a</td>
<td>S1</td>
<td></td>
</tr>
<tr>
<td>Stage IIIB</td>
<td>Any pT/TX</td>
<td>N1-3</td>
<td>M0</td>
<td>S2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Any pT/TX</td>
<td>Any N</td>
<td>M1A</td>
<td>S2</td>
<td></td>
</tr>
<tr>
<td>Stage IIIC</td>
<td>Any pT/TX</td>
<td>N1-3</td>
<td>M1a</td>
<td>S3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Any pT/TX</td>
<td>Any N</td>
<td>M1b</td>
<td>S3</td>
<td></td>
</tr>
</tbody>
</table>
## Prognosis table

Prognostic-based staging system for metastatic germ cell cancer (International Germ Cell Cancer Collaboration Group)

<table>
<thead>
<tr>
<th>Prognosis group</th>
<th>Non-seminoma</th>
<th>All of the following criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Good prognosis group</td>
<td></td>
<td>• Testis-retroperitoneal primary / No non-pulmonary visceral metatases / AFP &lt; 1.000 ng/ml / ß-hCG &lt; 5.000 mlU/L (1.000 ng/ml) / LDH &lt; 1.5 x ULN</td>
</tr>
<tr>
<td>Seminoma</td>
<td>56% of cases</td>
<td>5-year PFS 89%</td>
</tr>
<tr>
<td>5-year survival 92%</td>
<td>All of the following criteria:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Any primary site / No non-pulmonary visceral metatases / Normal AFP / Any ß-hCG / Any LDH</td>
<td></td>
</tr>
<tr>
<td>Seminoma</td>
<td>90% of cases</td>
<td>5-year PFS 82%</td>
</tr>
<tr>
<td>5-year survival 86%</td>
<td>All of the following criteria:</td>
<td></td>
</tr>
<tr>
<td>Intermediate prognosis group</td>
<td>Non-seminoma</td>
<td>28% of cases</td>
</tr>
<tr>
<td>5-year PFS 75%</td>
<td>5-year survival 80%</td>
<td></td>
</tr>
<tr>
<td>Poor prognosis group</td>
<td>Non-seminoma</td>
<td>Any of the following criteria:</td>
</tr>
<tr>
<td>16% of cases</td>
<td>5-year PFS 41%</td>
<td></td>
</tr>
<tr>
<td>5-year survival 48%</td>
<td>Any of the following criteria:</td>
<td></td>
</tr>
<tr>
<td>Seminoma</td>
<td>10% of cases</td>
<td>5-year PFS 67%</td>
</tr>
<tr>
<td>5-year survival 72%</td>
<td>Any of the following criteria:</td>
<td></td>
</tr>
<tr>
<td>Poor prognosis group</td>
<td>Non-seminoma</td>
<td>Any of the following criteria:</td>
</tr>
<tr>
<td>16% of cases</td>
<td>5-year PFS 41%</td>
<td></td>
</tr>
<tr>
<td>5-year survival 48%</td>
<td>Any of the following criteria:</td>
<td></td>
</tr>
<tr>
<td>Seminoma</td>
<td>10% of cases</td>
<td>5-year PFS 67%</td>
</tr>
<tr>
<td>5-year survival 72%</td>
<td>Any of the following criteria:</td>
<td></td>
</tr>
<tr>
<td>Poor prognosis group</td>
<td>Non-seminoma</td>
<td>Any of the following criteria:</td>
</tr>
<tr>
<td>16% of cases</td>
<td>5-year PFS 41%</td>
<td></td>
</tr>
<tr>
<td>5-year survival 48%</td>
<td>Any of the following criteria:</td>
<td></td>
</tr>
<tr>
<td>Seminoma</td>
<td>10% of cases</td>
<td>5-year PFS 67%</td>
</tr>
<tr>
<td>5-year survival 72%</td>
<td>Any of the following criteria:</td>
<td></td>
</tr>
</tbody>
</table>

PFS = progression-free survival / AFP = alpha-fetoprotein / ß-hCG = beta-human chorionic gonadotrophin / LDH = lactate dehydrogenase

Taken from EGCCCG guidelines
### Chemotherapy protocol for advanced disease

<table>
<thead>
<tr>
<th>Protocol</th>
<th>Cisplatin, mg/m² (30 min.-inf.)</th>
<th>Etoposide, mg/m² (30-60 min.-inf.)</th>
<th>Ifosfamide*, mg/m² (1h-inf.)</th>
<th>Bleomycin, mg/m² (IV bolus)</th>
<th>q day</th>
<th>No. Of cycles/prognosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>BEP.PEB &quot;5 DAYS&quot;</td>
<td>20d 1-5</td>
<td>100d 1-5</td>
<td>-</td>
<td>d 1,8,15</td>
<td>22</td>
<td>3</td>
</tr>
<tr>
<td>BEP.PEB &quot;3 DAYS&quot;</td>
<td>50d 1,2</td>
<td>165d 1,2,3</td>
<td>-</td>
<td>d 1,8,15</td>
<td>22</td>
<td>3</td>
</tr>
<tr>
<td>PE</td>
<td>20d 1-5</td>
<td>100d 1-5</td>
<td>-</td>
<td>-</td>
<td>22</td>
<td>4</td>
</tr>
<tr>
<td>PEI, VIP**</td>
<td>20d 1-5</td>
<td>75d 1-5</td>
<td>1200d 1-5</td>
<td>-</td>
<td>22-29</td>
<td>4</td>
</tr>
</tbody>
</table>

*Taken from EGCCCG guidelines*
<table>
<thead>
<tr>
<th>Title</th>
<th>Country</th>
<th>Year</th>
<th>Scope</th>
<th>AGREE overall assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>NICE: Improving outcomes in urological cancers [3]</td>
<td>UK</td>
<td>2002</td>
<td>Urological cancers</td>
<td>Recommend (with provisos or alterations)</td>
</tr>
<tr>
<td>The Royal College of radiologists COIN guidelines: Testicular Germ cell Tumours [4]</td>
<td>UK</td>
<td>1998</td>
<td>Testicular germ cell tumours</td>
<td>Recommend (with provisos or alterations)</td>
</tr>
<tr>
<td>European Association of Urology: Guidelines on Testicular Cancer [5]</td>
<td>Europe</td>
<td>2004</td>
<td>Testicular germ cell tumours</td>
<td>Recommend (with provisos or alterations)</td>
</tr>
<tr>
<td>NCCN: Testicular cancer [6]</td>
<td>USA</td>
<td>2005</td>
<td>Testicular germ cell tumours</td>
<td>Recommend (with provisos or alterations)</td>
</tr>
<tr>
<td>National Cancer Institute: Testicular cancer Treatment [9]</td>
<td>USA</td>
<td>2003</td>
<td>Testicular germ cell tumours</td>
<td>Recommend (with provisos or alterations)</td>
</tr>
<tr>
<td>Cancercare Ontario Program: Surveillance programs for early stage non-seminomatous testicular cancer [10]</td>
<td>Canada</td>
<td>2001</td>
<td>Non seminomatous testicular cancer</td>
<td>Recommend (with provisos or alterations)</td>
</tr>
</tbody>
</table>

The assessment of the guidelines was made with the AGREE instrument. All details can be found on the AGREE collaboration website: http://www.agreecollaboration.org/
The AGREE instrument can be found on: http://www.agreecollaboration.org/pdf/agreeinstrumentfinal.pdf
## Appendix 1

### Agree scores

#### Table of contents

<table>
<thead>
<tr>
<th>Key items</th>
<th>SIGN</th>
<th>NICE</th>
<th>NCCN</th>
<th>NCI</th>
<th>COIN</th>
<th>EAU</th>
<th>Cancer Care Ontario</th>
<th>EGCCCG</th>
<th>Oncoline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Scope and purpose</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>3</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td><strong>Stakeholder involvement</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>1</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>5</td>
<td>3</td>
<td>4</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>6</td>
<td>4</td>
<td>4</td>
<td>3</td>
<td>4</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>7</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td><strong>Rigour of development</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>4</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>4</td>
<td>3</td>
<td>4</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>9</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>2</td>
<td>4</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>10</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>2</td>
<td>4</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>11</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>12</td>
<td>4</td>
<td>2</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>13</td>
<td>4</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>4</td>
<td>2</td>
<td>4</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>14</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>4</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><strong>Clarity and presentation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>4</td>
<td>3</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>16</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>17</td>
<td>4</td>
<td>2</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>18</td>
<td>4</td>
<td>1</td>
<td>4</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><strong>Applicability</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>20</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>21</td>
<td>4</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><strong>Editorial independance</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>2</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>23</td>
<td>4</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><strong>Overall assessment</strong></td>
<td>SR</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>NR</td>
</tr>
</tbody>
</table>
Key to evidence statements and grades of recommendations

SCOTTISH INTERCOLLEGIATE GUIDELINES NETWORK (SIGN) [1]

Levels of evidence

1++ High quality meta-analyses, systematic reviews of RCTs or RCTs with a very low risk of bias
1+ Well conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias
1- Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias
2++ High quality systematic reviews of case control or cohort studies
2+ High quality case control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal
2- Case control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal
3 Non analytic studies, e.g. case reports, case series
4 Expert opinion

Grades of recommendation

A At least one meta-analysis, systematic review of RCTs, or RCT rated as 1++ and directly applicable to the target population; or body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results
B A body of evidence including studies rated as 2++, directly applicable to the target population, and demonstrating overall consistency of results; or Extrapolated evidence from studies rated as 1++ or 1+
C A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of results; or Extrapolated evidence from studies rated as 2++
D Evidence level 3 or 4; or Extrapolated evidence from studies rated as 2+

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE (NICE)

A Evidence derived from randomised controlled trials or systematic reviews of randomised trials
B Evidence from non-randomised controlled trials or observational studies
C Professional consensus
AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Level
I  Meta-analysis of multiple well designed, controlled studies; randomised trials with low falsepositive and low false-negative errors (high power)
II  At least one well designed experimental study; randomised trials with high false-positive or high false-negative errors or both (low power)
III  Well designed, quasi-experimental studies, such as nonrandomised controlled, single-group, preoperative-postoperative comparison, cohort, time, or matched case-control series
IV  Well designed, non experimental studies such as comparative and correlational descriptive and case studies
V  Case reports and clinical examples

Grade
A  Evidence of type I or consistent findings from multiple studies of type II, III or IV
B  Evidence of type II, III or IV and generally consistent findings
C  Evidence of type II, III or IV but inconsistent findings
D  Little or no systematic empirical evidence

NATIONAL CANCER INSTITUTE (NCI)

Strength of study design
- Randomised controlled clinical trials
- Double-blinded
- Non blinded (allocation schema or treatment delivery)
- Non randomised controlled clinical trials
- Case series
- Population-based, consecutive series
- Consecutive cases (not population series)
- Non consecutive cases
TESTICULAR CANCER

NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) [6]

Category 1 There is uniform NCCN consensus, based on high level evidence, that the recommendation is appropriate
Category 2A There is uniform NCCN consensus, based on lower-level evidence including clinical experience, that the recommendation is appropriate
Category 2B There is non uniform consensus (but no major disagreement), based on lower level evidence including clinical experience, that the recommendation is appropriate
Category 3 There is major NCCN disagreement that the recommendation is appropriate

European Association of Urology (see AHRQ)[61]

European Consensus on diagnosis and treatment of germ cell cancer [58]

Level IA Evidence obtained from meta-analysis of RCT and systematic reviews of RCT
Level IB Evidence obtained from at least one RCT
Level IIA Evidence obtained from at least one well-designed controlled study without randomisation
Level IIB Evidence obtained from at least one other type of well-designed quasiexperimental study
Level III Evidence obtained from well-designed non-experimental descriptive studies, such as comparative studies, correlation studies and case studies
Level IV Evidence obtained from expert committee or opinion and/or clinical experience of respected authorities without transparent proof.